Mitchell Kamrava1, Amar U Kishan2, Daniel J Margolis3, Jiaoti Huang4, Fred Dorey5, Patricia Lieu5, Patrick A Kupelian2, Leonard S Marks5. 1. Department of Radiation Oncology, University of California Los Angeles, Los Angeles, California. Electronic address: mkamrava@mednet.ucla.edu. 2. Department of Radiation Oncology, University of California Los Angeles, Los Angeles, California. 3. Department of Radiology, University of California Los Angeles, Los Angeles, California. 4. Department of Pathology, University of California Los Angeles, Los Angeles, California. 5. Department of Urology, University of California Los Angeles, Los Angeles, California.
Abstract
PURPOSE: Magnetic resonance imaging (MRI) guidance may improve the accuracy of Gleason score (GS) determination by directing the biopsy to regions of interest (ROI) that are likely to harbor high-grade prostate cancer (CaP). The aim of this study was to determine the frequency and predictors of GS upgrading when a subsequent MRI-guided biopsy is performed on patients with a diagnosis of GS 6 disease on the basis of conventional, transrectal ultrasound-guided biopsy. METHODS AND MATERIALS: A consecutive series of 245 men with a diagnosis of low-risk CaP (ie, cT1c, GS 6, prostate-specific antigen <10) based on transrectal ultrasound-guided biopsy was enrolled in an active surveillance protocol that used subsequent MRI-guided biopsy for confirmation of GS. ROIs were categorized on a scale of 1 to 5. The Artemis ultrasound-MRI fusion device was used to perform targeted biopsies of ROIs as well as systematic biopsies from a software-based 12-point map. Predictors of GS upgrading were analyzed using univariate and multivariate analyses. RESULTS: Fusion biopsy resulted in 26% of patients having GS upgrading (GS 3+4 in 18%, 4+3 in 5%, and 8-9 in 3%). Of the 72% of patients with ROIs appropriate for targeting, targeted cores upgraded the GS in 18%, whereas systematic cores upgraded the GS in 24%. In patients without targeted biopsy, GS upgrading was seen in 14%. On multivariate analysis, a category 5 ROI was the most significant predictor of GS upgrading with an odds ratio of 10.56 (P < .01). CONCLUSIONS: Nearly 25% of men with GS 6 CaP diagnosed by standard transrectal ultrasound biopsy may experience GS upgrading when a subsequent MRI-ultrasound fusion biopsy is performed. The most important single predictor of upgrading is a category 5 ROI on multiparametric MRI. GS upgrading may influence treatment decisions. Therefore, MRI-guided biopsy should be considered prior to formulating a management strategy in patients whose conventional biopsy reveals low-risk CaP.
PURPOSE: Magnetic resonance imaging (MRI) guidance may improve the accuracy of Gleason score (GS) determination by directing the biopsy to regions of interest (ROI) that are likely to harbor high-grade prostate cancer (CaP). The aim of this study was to determine the frequency and predictors of GS upgrading when a subsequent MRI-guided biopsy is performed on patients with a diagnosis of GS 6 disease on the basis of conventional, transrectal ultrasound-guided biopsy. METHODS AND MATERIALS: A consecutive series of 245 men with a diagnosis of low-risk CaP (ie, cT1c, GS 6, prostate-specific antigen <10) based on transrectal ultrasound-guided biopsy was enrolled in an active surveillance protocol that used subsequent MRI-guided biopsy for confirmation of GS. ROIs were categorized on a scale of 1 to 5. The Artemis ultrasound-MRI fusion device was used to perform targeted biopsies of ROIs as well as systematic biopsies from a software-based 12-point map. Predictors of GS upgrading were analyzed using univariate and multivariate analyses. RESULTS: Fusion biopsy resulted in 26% of patients having GS upgrading (GS 3+4 in 18%, 4+3 in 5%, and 8-9 in 3%). Of the 72% of patients with ROIs appropriate for targeting, targeted cores upgraded the GS in 18%, whereas systematic cores upgraded the GS in 24%. In patients without targeted biopsy, GS upgrading was seen in 14%. On multivariate analysis, a category 5 ROI was the most significant predictor of GS upgrading with an odds ratio of 10.56 (P < .01). CONCLUSIONS: Nearly 25% of men with GS 6 CaP diagnosed by standard transrectal ultrasound biopsy may experience GS upgrading when a subsequent MRI-ultrasound fusion biopsy is performed. The most important single predictor of upgrading is a category 5 ROI on multiparametric MRI. GS upgrading may influence treatment decisions. Therefore, MRI-guided biopsy should be considered prior to formulating a management strategy in patients whose conventional biopsy reveals low-risk CaP.
Authors: Jochen Walz; Markus Graefen; Felix K-H Chun; Andreas Erbersdobler; Alexander Haese; Thomas Steuber; Thorsten Schlomm; Hartwig Huland; Pierre I Karakiewicz Journal: Eur Urol Date: 2006-03-29 Impact factor: 20.096
Authors: Peter A Pinto; Paul H Chung; Ardeshir R Rastinehad; Angelo A Baccala; Jochen Kruecker; Compton J Benjamin; Sheng Xu; Pingkun Yan; Samuel Kadoury; Celene Chua; Julia K Locklin; Baris Turkbey; Joanna H Shih; Stacey P Gates; Carey Buckner; Gennady Bratslavsky; W Marston Linehan; Neil D Glossop; Peter L Choyke; Bradford J Wood Journal: J Urol Date: 2011-08-17 Impact factor: 7.450
Authors: Thomas Hambrock; Diederik M Somford; Caroline Hoeks; Stefan A W Bouwense; Henkjan Huisman; Derya Yakar; Inge M van Oort; J Alfred Witjes; Jurgen J Fütterer; Jelle O Barentsz Journal: J Urol Date: 2009-12-14 Impact factor: 7.450
Authors: Michael S Cohen; Robert S Hanley; Teodora Kurteva; Robin Ruthazer; Mark L Silverman; Andrea Sorcini; Karim Hamawy; Robert A Roth; Ingolf Tuerk; John A Libertino Journal: Eur Urol Date: 2008-03-28 Impact factor: 20.096
Authors: A V Taira; G S Merrick; R W Galbreath; H Andreini; W Taubenslag; R Curtis; W M Butler; E Adamovich; K E Wallner Journal: Prostate Cancer Prostatic Dis Date: 2009-09-29 Impact factor: 5.554
Authors: D Nörenberg; O Solyanik; B Schlenker; G Magistro; B Ertl-Wagner; D A Clevert; C Stief; M F Reiser; M D'Anastasi Journal: Urologe A Date: 2017-05 Impact factor: 0.639
Authors: A Pichon; Y Neuzillet; H Botto; J-P Raynaud; C Radulescu; V Molinié; J-M Herve; T Lebret Journal: Prostate Cancer Prostatic Dis Date: 2015-10-06 Impact factor: 5.554
Authors: Ardeshir R Rastinehad; Steven F Abboud; Arvin K George; Thomas P Frye; Richard Ho; Raju Chelluri; Michele Fascelli; Joanna Shih; Robert Villani; Eran Ben-Levi; Oksana Yaskiv; Baris Turkbey; Peter L Choyke; Maria J Merino; Bradford J Wood; Peter A Pinto Journal: J Urol Date: 2016-01-23 Impact factor: 7.450
Authors: Emanuel Darius Cata; Iulia Andras; Teodora Telecan; Attila Tamas-Szora; Radu-Tudor Coman; Dan-Vasile Stanca; Ioan Coman; Nicolae Crisan Journal: Med Pharm Rep Date: 2021-04-29
Authors: Ivo G Schoots; Daniel F Osses; Frank-Jan H Drost; Jan F M Verbeek; Sebastiaan Remmers; Geert J L H van Leenders; Chris H Bangma; Monique J Roobol Journal: Transl Androl Urol Date: 2018-02